vs
Side-by-side financial comparison of American Express (AXP) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
American Express is the larger business by last-quarter revenue ($18.9M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). American Express runs the higher net margin — 15.7% vs -0.8%, a 16.5% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -25.7%). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AXP vs CTMX — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $18.7M |
| Net Profit | $3.0M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | 15.7% | -0.8% |
| Revenue YoY | 11.4% | -25.7% |
| Net Profit YoY | 15.0% | 97.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.3B | $18.7M | ||
| Q1 25 | $9.6B | $50.9M | ||
| Q4 24 | $10.0B | $38.1M | ||
| Q3 24 | $9.7B | $33.4M | ||
| Q2 24 | $9.8B | $25.1M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | $-154.0K | ||
| Q1 25 | $2.6B | $23.5M | ||
| Q4 24 | $2.2B | $18.9M | ||
| Q3 24 | $2.5B | $5.7M | ||
| Q2 24 | $3.0B | $-6.5M |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 34.4% | -6.9% | ||
| Q1 25 | 34.6% | 44.4% | ||
| Q4 24 | 27.7% | 46.4% | ||
| Q3 24 | 33.0% | 12.3% | ||
| Q2 24 | 38.6% | -33.7% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | — | ||
| Q2 25 | 28.0% | -0.8% | ||
| Q1 25 | 26.8% | 46.2% | ||
| Q4 24 | 21.8% | 49.6% | ||
| Q3 24 | 25.8% | 17.2% | ||
| Q2 24 | 30.7% | -26.0% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | — | ||
| Q2 25 | $4.08 | — | ||
| Q1 25 | $3.64 | — | ||
| Q4 24 | $3.04 | — | ||
| Q3 24 | $3.49 | — | ||
| Q2 24 | $4.15 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | $60.4M | — |
| Stockholders' EquityBook value | $34.0M | $119.9M |
| Total Assets | $308.9M | $175.1M |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $197.0M | $49.0M | ||
| Q1 25 | $261.0M | $47.6M | ||
| Q4 24 | $221.0M | $38.1M | ||
| Q3 24 | $120.0M | $40.6M | ||
| Q2 24 | $188.0M | $43.2M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | — | ||
| Q3 25 | $32.4B | — | ||
| Q2 25 | $32.3B | $119.9M | ||
| Q1 25 | $31.2B | $25.0M | ||
| Q4 24 | $30.3B | $-456.0K | ||
| Q3 24 | $29.7B | $-23.5M | ||
| Q2 24 | $29.5B | $-31.2M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | — | ||
| Q3 25 | $297.6B | — | ||
| Q2 25 | $295.6B | $175.1M | ||
| Q1 25 | $282.2B | $98.5M | ||
| Q4 24 | $271.5B | $120.5M | ||
| Q3 24 | $271.0B | $139.0M | ||
| Q2 24 | $272.2B | $159.2M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $4.4B | $-15.8M | ||
| Q1 25 | $4.8B | $-21.0M | ||
| Q4 24 | $5.8B | $-19.9M | ||
| Q3 24 | $-1.8B | $-20.7M | ||
| Q2 24 | $4.5B | $-19.5M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $3.7B | $-15.8M | ||
| Q1 25 | $4.3B | $-21.2M | ||
| Q4 24 | $5.3B | $-20.0M | ||
| Q3 24 | $-2.3B | $-20.7M | ||
| Q2 24 | $4.0B | $-19.6M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 36.3% | -84.6% | ||
| Q1 25 | 45.0% | -41.6% | ||
| Q4 24 | 53.1% | -52.5% | ||
| Q3 24 | -23.3% | -62.1% | ||
| Q2 24 | 40.4% | -78.2% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 6.0% | 0.1% | ||
| Q1 25 | 4.5% | 0.2% | ||
| Q4 24 | 5.0% | 0.2% | ||
| Q3 24 | 4.7% | 0.1% | ||
| Q2 24 | 5.8% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | -0.89× | ||
| Q4 24 | 2.66× | -1.05× | ||
| Q3 24 | -0.72× | -3.61× | ||
| Q2 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
